Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1

Summary

This is a multicenter, multinational, open-label study of VTS-270 to evaluate the long-term safety and tolerability of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in participants transitioning from Study VTS301 (Parts A/B \[NCT02534844\] and Part C \[NCT04958642\]) with neurologic manifestations of Niemann-Pick Type C1 (NPC1) disease.

Timeline

Start

2019-12-02

Primary completion

2021-10-18

Completion

2021-10-18

Outcome

Outcome not reported

Stopped (Business): “Terminated by previous Sponsor decision”

Drugs

Indications